V-184 is under clinical development by Merck & Co and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect V-184’s likelihood of approval (LoA) and phase transition for Chikungunya Fever took place on 14 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their V-184 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

V-184 overview

V-184 is under development for the prophylaxis of chikungunya fever. It is a recombinant measles-virus-based vaccine. It is administered through intramuscular route as a suspention dosage form. The vaccine candidate is based on Themaxyn technology.

Merck & Co overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Quick View V-184 LOA Data

Report Segments
  • Innovator
Drug Name
  • V-184
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Merck & Co
  • Originator: Themis Bioscience
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.